![Mark S. Fineman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark S. Fineman
Keine laufenden Positionen mehr
Profil
Mark S.
Fineman worked as a Senior Director-Medical Development at Amylin Pharmaceuticals, Inc., Head-Clinical & Regulatory Affairs at Psylin Neurosciences, Inc., and Senior Vice President-Research & Development at Elcelyx Therapeutics, Inc. He holds a graduate degree from the University of California San Diego, an undergraduate degree from California Polytechnic State University (San Luis Obispo), and a doctorate degree from Vrije Universiteit Amsterdam.
Ehemalige bekannte Positionen von Mark S. Fineman
Unternehmen | Position | Ende |
---|---|---|
Amylin Pharmaceuticals, Inc.
![]() Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Psylin Neurosciences, Inc.
![]() Psylin Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Psylin Neurosciences, Inc. discovers and develops peptide hormones for the treatment of psychiatric disorders. The firm is formed in partnership between Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. The company was founded on January 30, 2007 and is located in San Diego, CA | Technik-/Wissenschafts-/F&E-Leiter | - |
Elcelyx Therapeutics, Inc.
![]() Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mark S. Fineman
California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
University of California San Diego | Graduate Degree |
Vrije Universiteit Amsterdam | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Elcelyx Therapeutics, Inc.
![]() Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Health Technology |
Amylin Pharmaceuticals, Inc.
![]() Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Psylin Neurosciences, Inc.
![]() Psylin Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Psylin Neurosciences, Inc. discovers and develops peptide hormones for the treatment of psychiatric disorders. The firm is formed in partnership between Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. The company was founded on January 30, 2007 and is located in San Diego, CA | Health Technology |